Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally.
Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.
The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease.
In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism.
Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 14, 24 | -18.95 Decreased by -2.05 K% | -0.81 Decreased by -2.24 K% |
| Mar 27, 24 | -1.16 Decreased by -33.33% | -0.97 Decreased by -19.59% |
| Nov 9, 23 | -0.85 Decreased by -21.43% | -0.61 Decreased by -39.34% |
| Aug 9, 23 | -0.52 Increased by +40.23% | -0.87 Increased by +40.23% |
| May 9, 23 | -0.88 Decreased by -76.00% | -1.07 Increased by +17.76% |
| Mar 23, 23 | -0.87 Decreased by -74.00% | -0.93 Increased by +6.45% |
| Nov 3, 22 | -0.70 Decreased by -180.00% | -0.68 Decreased by -2.94% |
| Aug 3, 22 | -0.87 Decreased by -4.25 K% | -0.68 Decreased by -27.94% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 2.34 M Increased by +4.05% | -1.42 M Increased by +43.53% | Decreased by -60.85% Increased by +45.73% |
| Mar 31, 24 | 2.05 M Decreased by -3.53% | -1.40 M Increased by +67.93% | Decreased by -68.14% Increased by +66.76% |
| Dec 31, 23 | 3.98 K Decreased by -99.84% | -5.73 M Increased by +72.60% | Decreased by -143.80 K% Decreased by -17.00 K% |
| Sep 30, 23 | 3.00 K Decreased by -99.84% | -4.14 M Decreased by -32.90% | Decreased by -138.17 K% Decreased by -82.29 K% |
| Jun 30, 23 | 2.25 M Increased by +1.11 K% | -2.52 M Increased by +40.30% | Decreased by -112.11% Decreased by -105.90% |
| Mar 31, 23 | 2.13 M Increased by +40.28% | -4.36 M Decreased by -76.81% | Decreased by -204.98% Decreased by -26.05% |
| Dec 31, 22 | 2.48 M Increased by +159.94% | -20.90 M Decreased by -622.15% | Decreased by -841.01% Decreased by -177.82% |
| Sep 30, 22 | 1.86 M Increased by +208.97% | -3.12 M Decreased by -83.69% | Decreased by -167.69% Increased by +40.55% |